More published evidence counters use of atypical antipsychotics in dementia
More evidence to counter the use of atypical antipsychotic drugs in dementia has been published.
Earlier this year, the Committee on Safety of Medicines highlighted trials
showing an increased risk of stroke with risperidone (Risperdal) and
olanzapine (Zyprexa) used in this context. A new systematic review looks
at the use of atypical antipsychotic agents in treating behavioural and
psychological symptoms of dementia. However, it identified only five
published randomised trials evaluating these drugs.
The review, by Canadian researchers, concludes that improvements were
often seen with both the active agent and placebo. The authors comment
on the short duration of the trials, with none lasting longer than 12
weeks. They comment that patients are often maintained on these drugs
for months.
The authors say that, although atypical
antipsychotic drugs are being used with increasing frequency in dementia,
further evidence is required before such use can be endorsed, particularly
in light of potential adverse events (BMJ 2004;329:75). |
The
Pharmaceutical Journal
Acrobat
Reader